CN114173788A - 泪液分泌促进用眼科组合物 - Google Patents

泪液分泌促进用眼科组合物 Download PDF

Info

Publication number
CN114173788A
CN114173788A CN202080055566.8A CN202080055566A CN114173788A CN 114173788 A CN114173788 A CN 114173788A CN 202080055566 A CN202080055566 A CN 202080055566A CN 114173788 A CN114173788 A CN 114173788A
Authority
CN
China
Prior art keywords
ophthalmic composition
salt
eye
digoxitinib
promoting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080055566.8A
Other languages
English (en)
Chinese (zh)
Inventor
高井良宏
黑濑孝弘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rohto Pharmaceutical Co Ltd
Original Assignee
Rohto Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rohto Pharmaceutical Co Ltd filed Critical Rohto Pharmaceutical Co Ltd
Priority to CN202410802175.8A priority Critical patent/CN118903144A/zh
Publication of CN114173788A publication Critical patent/CN114173788A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080055566.8A 2019-08-07 2020-08-06 泪液分泌促进用眼科组合物 Pending CN114173788A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410802175.8A CN118903144A (zh) 2019-08-07 2020-08-06 泪液分泌促进用眼科组合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2019145670 2019-08-07
JP2019-145670 2019-08-07
JP2019239605 2019-12-27
JP2019-239605 2019-12-27
PCT/JP2020/030231 WO2021025129A1 (ja) 2019-08-07 2020-08-06 涙液分泌促進用眼科組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410802175.8A Division CN118903144A (zh) 2019-08-07 2020-08-06 泪液分泌促进用眼科组合物

Publications (1)

Publication Number Publication Date
CN114173788A true CN114173788A (zh) 2022-03-11

Family

ID=74503644

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080055566.8A Pending CN114173788A (zh) 2019-08-07 2020-08-06 泪液分泌促进用眼科组合物
CN202410802175.8A Pending CN118903144A (zh) 2019-08-07 2020-08-06 泪液分泌促进用眼科组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410802175.8A Pending CN118903144A (zh) 2019-08-07 2020-08-06 泪液分泌促进用眼科组合物

Country Status (7)

Country Link
US (1) US20220280515A1 (https=)
EP (1) EP4011450A4 (https=)
JP (2) JP7597714B2 (https=)
KR (1) KR20220044288A (https=)
CN (2) CN114173788A (https=)
TW (1) TW202120094A (https=)
WO (1) WO2021025129A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116568285A (zh) * 2020-07-30 2023-08-08 乐敦制药株式会社 水性组合物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4674401A3 (en) * 2019-12-27 2026-02-25 Rohto Pharmaceutical Co., Ltd Container accommodating an aqueous ophthalmic composition comprising delgocitinib
US20230285564A1 (en) * 2020-07-30 2023-09-14 Rohto Pharmaceutical Co., Ltd. Aqueous Composition
JP2025014078A (ja) * 2021-11-30 2025-01-29 興和株式会社 新規ニコチンアミド化合物及びその用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101743009A (zh) * 2007-07-11 2010-06-16 辉瑞大药厂 治疗干眼病的药物组合物和方法
CN102510865A (zh) * 2009-07-31 2012-06-20 日本烟草产业株式会社 含氮螺环化合物及其药物用途
CN107709337A (zh) * 2015-07-07 2018-02-16 日本烟草产业株式会社 7H‑吡咯并[2，3‑d]嘧啶衍生物的制备方法和其中间体
WO2018117153A1 (en) * 2016-12-21 2018-06-28 Japan Tobacco Inc. Crystalline forms of a janus kinase inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102306276B1 (ko) * 2013-10-21 2021-09-30 니뽄 다바코 산교 가부시키가이샤 안질환의 치료제 또는 예방제
KR102702286B1 (ko) 2016-12-21 2024-09-04 니뽄 다바코 산교 가부시키가이샤 7H-피롤로[2,3-d]피리미딘 유도체의 제조 방법 및 그의 공결정
JP7722931B2 (ja) * 2019-12-27 2025-08-13 ロート製薬株式会社 水性組成物
EP4674401A3 (en) * 2019-12-27 2026-02-25 Rohto Pharmaceutical Co., Ltd Container accommodating an aqueous ophthalmic composition comprising delgocitinib
US20230285564A1 (en) * 2020-07-30 2023-09-14 Rohto Pharmaceutical Co., Ltd. Aqueous Composition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101743009A (zh) * 2007-07-11 2010-06-16 辉瑞大药厂 治疗干眼病的药物组合物和方法
CN102510865A (zh) * 2009-07-31 2012-06-20 日本烟草产业株式会社 含氮螺环化合物及其药物用途
CN107709337A (zh) * 2015-07-07 2018-02-16 日本烟草产业株式会社 7H‑吡咯并[2，3‑d]嘧啶衍生物的制备方法和其中间体
WO2018117153A1 (en) * 2016-12-21 2018-06-28 Japan Tobacco Inc. Crystalline forms of a janus kinase inhibitor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116568285A (zh) * 2020-07-30 2023-08-08 乐敦制药株式会社 水性组合物

Also Published As

Publication number Publication date
JP2025019313A (ja) 2025-02-06
TW202120094A (zh) 2021-06-01
EP4011450A4 (en) 2023-08-09
CN118903144A (zh) 2024-11-08
KR20220044288A (ko) 2022-04-07
WO2021025129A1 (ja) 2021-02-11
EP4011450A1 (en) 2022-06-15
US20220280515A1 (en) 2022-09-08
JP7597714B2 (ja) 2024-12-10
JPWO2021025129A1 (https=) 2021-02-11

Similar Documents

Publication Publication Date Title
JP7597714B2 (ja) 涙液分泌促進用眼科組成物
RS63136B9 (sr) Lekoviti sastav koji sadrži tivozanib
KR102902220B1 (ko) 4-페닐부티르산을 함유하는 노시의 치료 또는 예방제
TW202038966A (zh) 包含熊去氧膽酸之老花眼之治療或預防劑
US10973758B2 (en) Methods of eye treatment using therapeutic compositions containing dipyridamole
US10688113B2 (en) Methods of treating eye pain with aminophosphinic derivatives
WO2016171152A1 (ja) 角膜障害の治療剤、改善剤または予防剤
JP4933897B2 (ja) 眼内移行性促進水性点眼剤
WO2018147409A1 (ja) 水性点眼点鼻用組成物
US8268824B2 (en) Therapeutic agent for corneal disease
JP2012250951A (ja) アデノシン誘導体とプロスタグランジン類とβ受容体遮断薬の組合せ剤
PT2692345T (pt) Composição farmacêutica para prevenir ou tratar a degeneração macular
CN107106566A (zh) 晶状体硬化抑制剂
TW304879B (https=)
HK40066213A (zh) 泪液分泌促进用眼科组合物
JP2012250953A (ja) アデノシン誘導体とα２受容体作動薬の組合せ剤
JP2012250949A (ja) アデノシン誘導体と炭酸脱水酵素阻害剤とβ受容体遮断薬の組合せ剤
RU2836815C1 (ru) Офтальмологические композиции для местного применения на ксантановой основе с сокращенным режимом дозирования
JP2012250947A (ja) アデノシン誘導体とβ受容体遮断薬の組合せ剤
JP7197112B2 (ja) 水泡性角膜症治療用医薬組成物
US20110092509A1 (en) Pharmaceutical Composition for Prevention or Treatment of Disease Associated with Tear Reduction
JP2012250950A (ja) アデノシン誘導体とプロスタグランジン類の組合せ剤
JP2012250948A (ja) アデノシン誘導体と炭酸脱水酵素阻害剤の組合せ剤
JP2012250952A (ja) アデノシン誘導体とＲｈｏキナーゼ阻害剤の組合せ剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40066213

Country of ref document: HK